ProCE Banner Activity

CME

Congress to Clinic: Myeloid Malignancies Clinical Advances Journal Club on Emerging MPN, MDS, and AML Data

Video

On-demand webcast of expert faculty presentation and case discussion on emerging data in myeloid malignancies and how these data will impact your clinical practice when treating myeloproliferative neoplasms, myelodysplastic syndromes, and acute myeloid leukemia.

Physicians: Maximum of 1.50 AMA PRA Category 1 Credits

Released: July 19, 2024

Expiration: July 18, 2025

Share

Faculty

Courtney DiNardo

Courtney DiNardo, MD, MSCE

Professor of Medicine
Department of Leukemia
MD Anderson Cancer Center
Houston, Texas

Brady L. Stein

Brady L. Stein, MD, MHS

Professor of Medicine
Department of Hematology/Oncology
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Eunice S. Wang

Eunice S. Wang, MD

Chief, Leukemia and Benign Hematology Service
Professor of Oncology
Roswell Park Comprehensive Cancer Center
Buffalo, New York

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by an educational grant from Bristol-Myers Squibb

Bristol Myers Squibb

Target Audience

This educational program is intended for hematologists, medical oncologists, and other healthcare professionals who treat patients with MDS, AML, and MPN’s.

Program Learning Goal

The goal of this program is to improve the knowledge, competence, and performance of learners in effort to optimize treatment for patients with Hematologic Malignancies.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Evaluate emerging data in first-line treatment of low-risk MDS considering the potential impact of safety and efficacy results on clinical practice

  • Apply the latest advances from studies to practice and guideline recommendations when individualizing a therapeutic strategy for the management of AML​

  • Plan an optimal therapeutic sequence for patients with MPNs based on the latest clinical trial data

  • Determine if individual patients with MDS, AML, or MPNs are candidates for an ongoing investigational clinical trial and counsel patients on the investigational agents or drug combinations and the potential for trial enrollment

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Courtney DiNardo, MD, MSCE

Professor of Medicine
Department of Leukemia
MD Anderson Cancer Center
Houston, Texas

Courtney DiNardo, MD, MSCE: consultant/advisor/speaker: AbbVie, AstraZeneca, Bristol Myers Squibb, Genmab, GlaxoSmithKline, Notable Labs, Rigel, Schrödinger, Servier; researcher: AbbVie, Astex, Bristol Myers Squibb, Foghorn, Jazz, Schrödinger, Servier.

Brady L. Stein, MD, MHS

Professor of Medicine
Department of Hematology/Oncology
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Brady L. Stein, MD, MHS, has no relevant financial relationships to disclose. 

Eunice S. Wang, MD

Chief, Leukemia and Benign Hematology Service
Professor of Oncology
Roswell Park Comprehensive Cancer Center
Buffalo, New York

Eunice S. Wang, MD: consultant/advisor/speaker: AbbVie, Blueprint, Bristol Myers Squibb, CTI Biopharma, Daiichi Sankyo, Gilead, GlaxoSmithKline, Immunogen, Johnson & Johnson, Kite, Kura, Novartis, Qiagen, Rigel, Schrodinger, Sellas, Stemline, Sumitomo, Syndax.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from July 19, 2024, through July 18, 2025:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME Passport

A logo for a companyDescription automatically generated

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit www.cmepassport.org to create your account.